The trading price of ImmunityBio Inc (NASDAQ:IBRX) closed lower on Thursday, March 29, closing at $5.37, -1.65% lower than its previous close.
In examining the 52-week price action we see that the stock hit a 52-week high of $6.93 and a 52-week low of $1.25. Over the past month, the stock has gained 18.02% in value.
ImmunityBio Inc, whose market valuation is $3.62 billion at the time of this writing, is expected to release its quarterly earnings report Mar 12, 2024 – Mar 16, 2024. Investors’ optimism about the company’s current quarter earnings report is understandable. Analysts have predicted the quarterly earnings per share to grow by -$0.16 per share this quarter, however they have predicted annual earnings per share of -$0.68 for 2024 and -$0.45 for 2025. It means analysts are expecting annual earnings per share growth of 40.90% this year and 33.80% next year.
Analysts have forecast the company to bring in revenue of $20k for the current quarter, with the likely lows of $20k and highs of $20k. The average estimate suggests sales will likely down by -94.40% this quarter compared to what was recorded in the comparable quarter last year. From the analysts’ viewpoint, the consensus estimate for the company’s annual revenue in 2024 is $9.68 million. The company’s revenue is forecast to grow by 1,456.30% over what it did in 2024.
A company’s earnings reviews provide a brief indication of a stock’s direction in the short term, where in the case of ImmunityBio Inc No upward and no downward comments were posted in the last 7 days. On the technical side, indicators suggest IBRX has a 100% Buy on average for the short term. According to the data of the stock’s medium term indicators, the stock is currently averaging as a 100% Buy, while an average of long term indicators suggests that the stock is currently 100% Buy.
A quick review shows that IBRX’s price is currently 2.12% off the SMA20 and 18.21% off the SMA50. The RSI metric on the 14-day chart is currently showing 53.31, and weekly volatility stands at 14.01%. When measured over the past 30 days, the indicator reaches 9.90%. ImmunityBio Inc (NASDAQ:IBRX)’s beta value is currently sitting at 1.10, while the Average True Range indicator is currently displaying 0.55.
To see how ImmunityBio Inc stock has been performing in comparison to its peers in the industry, here are the numbers: IBRX stock’s performance was -1.65% in the latest trading, and 223.49% in the past year.
An evaluation of the daily trading volume of ImmunityBio Inc (NASDAQ:IBRX) indicates that the 3-month average is 4.01 million. However, this figure has increased over the past 10 days to an average of 5.12 million.
Currently, records show that 670.87 million of the company’s shares remain outstanding. The insiders hold 80.43% of outstanding shares, whereas institutions hold 8.49%. The stats also highlight that short interest as of Mar 15, 2024, stood at 53.25 million shares, resulting in a short ratio of 11.17 at that time. From this, we can conclude that short interest is 7.90% of the company’s total outstanding shares. It is noteworthy that short shares in March were up slightly from the previous month’s figure, which was 47.14 million. However, since the stock’s price has seen 6.97% year-to-date, investors’ interest is likely to be reignited due to its potential to move even higher.
